Opportunities

If you are interested in investing in or partnering with us to develop this technology for your needs, please contact us here

Benefit: Non-toxic, highly effective delivery technology for macromolecular drugs such as siRNA or CRISPR-Cas9 that doesn’t require synthetic lipids or polycations. Exosome loading technology that is non-disruptive, unlike extrusion or electroporation, and does not require expressing genes fused to exosome membrane components in the host cell. Hijacking nature’s own solutions to access the cytosol or load large, membrane impervious macromolecules into exosomes which can subsequently be used to treat recipient cells. Additionally, the cargo can be adapted to the desired sequence and hence pathology.

Opportunity: The University of Greenwich owns this IP and has granted a worldwide exclusive licence to Exogenix Ltd. Exogenix Ltd is seeking partners for the development and commercialisation of these technologies in the major territories.

IP Status: Patent protection exists for both the exosome loading technology in the form of patent application (WO/2020/030923) and for the exosome free delivery technology (WO2014203008).